Evaluation of the Activity Levels of Rat FVIII and Human FVIII Delivered by Adeno-associated Viral Vectors Both in Vitro and in Vivo

Overview

Journal Blood Cells Mol Dis

Specialty Hematology

Date 2018 Sep 26

PMID 30249384

Citations 3

Authors

Wei Zhang

Jianhua Mao

Yan Shen

Guowei Zhang

Yanyan Shao

Zheng Ruan

Yun Wang

Wenman Wu

Xuefeng Wang

Jiang Zhu

Saijuan Chen

Weidong Xiao

Xiaodong Xi

Affiliations

Soon will be listed here.

Abstract

The development of a novel coagulation factor VIII (FVIII) expression cassette with an enhanced activity for gene therapy of hemophilia A (HA) is essential. The biological properties of several non-human FVIII sequences, such as porcine and canine, have been evaluated. Here, we compared the activity level of rat FVIII (rFVIII) and human FVIII (hFVIII) by using single-chain and dual-chain strategies in 293 T cells and the HA mice. In both in vitro and hydrodynamic injection studies, the activity of rFVIII detected by the activated partial thromboplastin time assay was higher than that of hFVIII both by single-chain (~2.96-fold and ~1.72-fold, respectively) and dual-chain (~7.69-fold and ~2.35-fold, respectively). Moreover, the dual chain exerted a potentially higher delivery efficacy compared with the single chain (~4.96-fold and ~2.99-fold, respectively). The blood loss of HA mice administrated with rFVIII was less than those with hFVIII. AAV-delivered rFVIII and hFVIII also exerted long-term therapeutic effects on HA mice and caused a transient ALT elevation. These data might help to the development of novel, optimized FVIII expression cassettes based on the amino acid difference between rFVIII and hFVIII. These data indicate that the dual-chain strategy would likely enhance the delivery efficiency of the AAV-mediated FVIII gene therapy.

Citing Articles

Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances.

Suda T, Yokoo T, Kanefuji T, Kamimura K, Zhang G, Liu D Pharmaceutics. 2023; 15(4).

PMID: 37111597 PMC: 10141091. DOI: 10.3390/pharmaceutics15041111.

Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.

Mao J, Wang Y, Zhang W, Shen Y, Zhang G, Xi W Front Med. 2022; 16(4):584-595.

PMID: 35038106 DOI: 10.1007/s11684-021-0844-7.

Mechanistic Insights into Factor VIII Immune Tolerance Induction via Prenatal Cell Therapy in Hemophilia A.

Rodriguez M, Porada C, Almeida-Porada G Curr Stem Cell Rep. 2020; 5(4):145-161.

PMID: 32351874 PMC: 7189775. DOI: 10.1007/s40778-019-00165-y.

References

Chuah M, Collen D, Vandendriessche T . Preclinical and clinical gene therapy for haemophilia. Haemophilia. 2004; 10 Suppl 4:119-25. DOI: 10.1111/j.1365-2516.2004.00984.x. View

Dong B, Nakai H, Xiao W . Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther. 2009; 18(1):87-92. PMC: 2803017. DOI: 10.1038/mt.2009.258. View

Chen L, Zhu F, Li J, Lu H, Jiang H, Sarkar R . The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther. 2007; 15(10):1856-62. PMC: 2596977. DOI: 10.1038/sj.mt.6300268. View

Connelly S, Mount J, Mauser A, Gardner J, Kaleko M, McClelland A . Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood. 1996; 88(10):3846-53. View

Mah C, Sarkar R, Zolotukhin I, Schleissing M, Xiao X, Kazazian H . Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice. Hum Gene Ther. 2003; 14(2):143-52. DOI: 10.1089/104303403321070838. View

Zhou J, Ding Q, Chen Y, Ouyang Q, Jiang L, Dai J . Clinical features and molecular basis of 102 Chinese patients with congenital dysfibrinogenemia. Blood Cells Mol Dis. 2015; 55(4):308-15. DOI: 10.1016/j.bcmd.2015.06.002. View

Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan C . Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood. 2006; 108(1):107-15. DOI: 10.1182/blood-2005-12-5115. View

Sarkar R, Xiao W, Kazazian Jr H . A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J Thromb Haemost. 2003; 1(2):220-6. DOI: 10.1046/j.1538-7836.2003.00096.x. View

Nathwani A, Nienhuis A, Davidoff A . Current status of gene therapy for hemophilia. Curr Hematol Rep. 2003; 2(4):319-27. View

10.

Mahdi A, Obaji S, Collins P . Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol. 2015; 169(6):768-76. DOI: 10.1111/bjh.13360. View

11.

Wang Q, Dong B, Firrman J, Roberts S, Moore A, Cao W . Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery. Hum Gene Ther Methods. 2014; 25(4):261-8. PMC: 4142791. DOI: 10.1089/hgtb.2014.093. View

12.

Zhu F, Liu Z, Wang X, Miao J, Qu H, Chi X . Inter-chain disulfide bond improved protein trans-splicing increases plasma coagulation activity in C57BL/6 mice following portal vein FVIII gene delivery by dual vectors. Sci China Life Sci. 2013; 56(3):262-7. DOI: 10.1007/s11427-013-4455-7. View

13.

Sarkar R, Mucci M, Addya S, Tetreault R, Bellinger D, Nichols T . Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther. 2006; 17(4):427-39. DOI: 10.1089/hum.2006.17.427. View

14.

Vandendriessche T, Vanslembrouck V, Goovaerts I, Zwinnen H, Vanderhaeghen M, Collen D . Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci U S A. 1999; 96(18):10379-84. PMC: 17896. DOI: 10.1073/pnas.96.18.10379. View

15.

Nathwani A, Tuddenham E, Rangarajan S, Rosales C, McIntosh J, Linch D . Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011; 365(25):2357-65. PMC: 3265081. DOI: 10.1056/NEJMoa1108046. View

16.

Wang Q, Dong B, Firrman J, Wu W, Roberts S, Moore A . Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment. Gene Ther. 2016; 23(7):597-605. PMC: 4936945. DOI: 10.1038/gt.2016.34. View

17.

Spencer H, Riley B, Doering C . State of the art: gene therapy of haemophilia. Haemophilia. 2016; 22 Suppl 5:66-71. DOI: 10.1111/hae.13011. View

18.

Doering C, Healey J, Parker E, Barrow R, Lollar P . High level expression of recombinant porcine coagulation factor VIII. J Biol Chem. 2002; 277(41):38345-9. DOI: 10.1074/jbc.M206959200. View

19.

Peyvandi F, Garagiola I, Young G . The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016; 388(10040):187-97. DOI: 10.1016/S0140-6736(15)01123-X. View

20.

Laffan M . New products for the treatment of haemophilia. Br J Haematol. 2015; 172(1):23-31. DOI: 10.1111/bjh.13797. View